It has been reported that high simultaneous doses of CD3+ and CD34+ cells and high CD3+/T regulatory (Treg) ratio in grafts for children with major thalassemia and acute myeloid leukemia (AML) patients increased the rate of acute GVHD.12, 13. This evidence concerns the gene CD34 and acute myeloid leukemia.